Originator Organization Adcentrx Therapeutics, Inc.Startup |
Active Organization Adcentrx Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H62N6O5S |
InChIKeyVNKVPXRCRUDPAH-JYZGKHMWSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Adcentrx Therapeutics, Inc.Startup | 17 Apr 2024 |